Want to see JP:4588 full AI Analyst Report?
4588 Stock Chart & Stats
¥953.00
-¥1.00(-0.20%)
At close: 4:00 PM EST
¥953.00
-¥1.00(-0.20%)
Day’s Range― - ―
52-Week Range¥571.00 - ¥3,695.00
Previous CloseN/A
Volume332.10K
Average Volume (3M)1.52M
Market Cap
¥72.12B
Enterprise Value¥60.34K
Total Cash (Recent Filing)¥3.72B
Total Debt (Recent Filing)¥320.02M
Price to Earnings (P/E)―
Beta2.09
Next Earnings
Aug 07, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-81.78
Shares Outstanding29,319,700
10 Day Avg. Volume2,742,450
30 Day Avg. Volume1,517,566
Financial Highlights & Ratios
PEG Ratio-4.72
Price to Book (P/B)8.90
Price to Sales (P/S)1247.26
P/FCF Ratio-18.32
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Healthy Balance Sheet / Low LeverageImproved debt-to-equity and a meaningful rise in equity and assets provide structural financial capacity to support clinical programs and partnering negotiations over the next several months. Manageable leverage reduces immediate refinancing pressure and gives time to secure milestones or partnerships.
High Gross Margins On Reported RevenueVery high gross margins on the modest revenue base imply collaboration/licensing income is largely non-costly, so incremental partnership payments or milestone receipts can drop to the operating line. This structural margin profile supports scalability if R&D deals or approvals materialize.
Partnership-driven, Capital-light Business ModelA business model centered on collaborations, licensing and grants reduces the need for large commercial infrastructure and enables non-dilutive or milestone-linked funding. Structurally this suits early-stage biotech, allowing progress via partners while limiting fixed-cost scaling requirements.
Bears Say
Persistent, Large Cash BurnConsistent multi-year operating and free cash flow outflows mean the company cannot self-fund development indefinitely. This structural cash burn necessitates recurrent external financing or deal-dependent milestone receipts, increasing dilution and constraining strategic options over the medium term.
Multi-year Revenue CollapseA dramatic, sustained revenue decline materially reduces operating leverage and bargaining power with partners. The shrunken top line makes fixed R&D and G&A burdens harder to cover, raising the bar for any revenue inflection to materially improve fundamentals within a 2–6 month horizon.
Large And Persistent Operating LossesContinued multi-year operating deficits erode equity and limit flexibility to invest in multiple programs. Even with modest debt, persistent negative returns increase the probability of dilution, program prioritization or external funding at unfavorable terms, impairing long-term program continuity.
Oncolys BioPharma, Inc. News
4588 FAQ
What was Oncolys BioPharma, Inc.’s price range in the past 12 months?
Oncolys BioPharma, Inc. lowest stock price was ¥571.00 and its highest was ¥3695.00 in the past 12 months.
What is Oncolys BioPharma, Inc.’s market cap?
Oncolys BioPharma, Inc.’s market cap is ¥72.12B.
When is Oncolys BioPharma, Inc.’s upcoming earnings report date?
Oncolys BioPharma, Inc.’s upcoming earnings report date is Aug 07, 2026 which is in 6 days.
How were Oncolys BioPharma, Inc.’s earnings last quarter?
Oncolys BioPharma, Inc. released its earnings results on May 08, 2026. The company reported -¥14.16 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Oncolys BioPharma, Inc. overvalued?
According to Wall Street analysts Oncolys BioPharma, Inc.’s price is currently Overvalued.
Does Oncolys BioPharma, Inc. pay dividends?
Oncolys BioPharma, Inc. does not currently pay dividends.
What is Oncolys BioPharma, Inc.’s EPS estimate?
Oncolys BioPharma, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Oncolys BioPharma, Inc. have?
Oncolys BioPharma, Inc. has 29,319,700 shares outstanding.
What happened to Oncolys BioPharma, Inc.’s price movement after its last earnings report?
Oncolys BioPharma, Inc. reported an EPS of -¥14.16 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 2.819%.
Which hedge fund is a major shareholder of Oncolys BioPharma, Inc.?
Currently, no hedge funds are holding shares in JP:4588
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Oncolys BioPharma, Inc.
Oncolys BioPharma Inc. is a biotechnology firm dedicated to the research, development, manufacturing, sales, and distribution of oncolytic viruses, pharmaceutical drugs, and diagnostic agents for tumors across Japan, other Asian regions, and the United States. Its robust pipeline features Telomelysin (OBP-301), an oncolytic adenovirus, currently in Phase II clinical trials for the treatment of gastric, gastroesophageal junction, head and neck, and esophageal cancers, and in Phase I trials for hepatocellular carcinoma. Other key developments include OBP-702, a telomerase-specific oncolytic adenovirus in preclinical stages for solid tumors; OBP-2011, also preclinical, targeting SARS-CoV-2 infection; OBP-601 (Censavudine), a nucleotide reverse transcriptase inhibitor that has completed Phase IIb clinical trials for HIV; and OBP-801, a histone deacetylase inhibitor, which is in Phase I clinical trials for solid tumors and preclinical assessment for ophthalmic applications. Additionally, the company is advancing TelomeScan (OBP-401 and OBP-1101), a cancer detection drug designed to identify living circulating tumor cells in cancer patients' blood. Oncolys BioPharma also offers diagnostic medications and inspection services. The company boasts various licensing and collaborative agreements with institutions such as Okayama University, Osaka University, Kyoto Prefectural University of Medicine, Kagoshima University, Astellas Pharma Inc., Yale University, Biologics Consulting Group, Inc., Lonza Houston, Inc., Medigen Biotechnology Corp., and Liquid Biotech USA, Inc. Founded in 2004, Oncolys BioPharma Inc. is based in Tokyo, Japan.